Anti-Lamin A + C antibody [EPR4519(2)] (ab169532)


  • Product name
    Anti-Lamin A + C antibody [EPR4519(2)]
    See all Lamin A + C primary antibodies
  • Description
    Rabbit monoclonal [EPR4519(2)] to Lamin A + C
  • Host species
  • Specificity
    ab169532 recognizes full length Lamin A + C and cleaved large unit.
  • Tested applications
    Suitable for: WB, IHC-Pmore details
    Unsuitable for: Flow Cyt,ICC or IP
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide corresponding to Human Lamin A + C.

  • Positive control
    • PC-12, THP-1, HeLa + Staurosporine and HeLa cell lysates; Human skin and Human uterus tissues.
  • General notes

    This product is a recombinant rabbit monoclonal antibody.

    A trial size is available to purchase for this antibody.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents



Our Abpromise guarantee covers the use of ab169532 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/10000 - 1/50000. Predicted molecular weight: 74 kDa.
IHC-P 1/250 - 1/500.
  • Application notes
    Is unsuitable for Flow Cyt,ICC or IP.
  • Target

    • Function
      Lamins are components of the nuclear lamina, a fibrous layer on the nucleoplasmic side of the inner nuclear membrane, which is thought to provide a framework for the nuclear envelope and may also interact with chromatin. Lamin A and C are present in equal amounts in the lamina of mammals. Play an important role in nuclear assembly, chromatin organization, nuclear membrane and telomere dynamics.
      Prelamin-A/C can accelerate smooth muscle cell senescence. It acts to disrupt mitosis and induce DNA damage in vascular smooth muscle cells (VSMCs), leading to mitotic failure, genomic instability, and premature senescence.
    • Tissue specificity
      In the arteries, prelamin-A/C accumulation is not observed in young healthy vessels but is prevalent in medial vascular smooth muscle celle (VSMCs) from aged individuals and in atherosclerotic lesions, where it often colocalizes with senescent and degenerate VSMCs. Prelamin-A/C expression increases with age and disease. In normal aging, the accumulation of prelamin-A/C is caused in part by the down-regulation of ZMPSTE24/FACE1 in response to oxidative stress.
    • Involvement in disease
      Defects in LMNA are the cause of Emery-Dreifuss muscular dystrophy type 2 (EDMD2) [MIM:181350]. A degenerative myopathy characterized by weakness and atrophy of muscle without involvement of the nervous system, early contractures of the elbows, Achilles tendons and spine, and cardiomyopathy associated with cardiac conduction defects.
      Defects in LMNA are the cause of cardiomyopathy dilated type 1A (CMD1A) [MIM:115200]. Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.
      Defects in LMNA are the cause of familial partial lipodystrophy type 2 (FPLD2) [MIM:151660]; also known as familial partial lipodystrophy Dunnigan type. A disorder characterized by the loss of subcutaneous adipose tissue in the lower parts of the body (limbs, buttocks, trunk). It is accompanied by an accumulation of adipose tissue in the face and neck causing a double chin, fat neck, or cushingoid appearance. Adipose tissue may also accumulate in the axillae, back, labia majora, and intraabdominal region. Affected patients are insulin-resistant and may develop glucose intolerance and diabetes mellitus after age 20 years, hypertriglyceridemia, and low levels of high density lipoprotein cholesterol.
      Defects in LMNA are the cause of limb-girdle muscular dystrophy type 1B (LGMD1B) [MIM:159001]. LGMD1B is an autosomal dominant degenerative myopathy with age-related atrioventricular cardiac conduction disturbances, dilated cardiomyopathy, and the absence of early contractures. LGMD1B is characterized by slowly progressive skeletal muscle weakness of the hip and shoulder girdles. Muscle biopsy shows mild dystrophic changes.
      Defects in LMNA are the cause of Charcot-Marie-Tooth disease type 2B1 (CMT2B1) [MIM:605588]. CMT2B1 is a form of Charcot-Marie-Tooth disease, the most common inherited disorder of the peripheral nervous system. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathy or CMT1, and primary peripheral axonal neuropathy or CMT2. Neuropathies of the CMT2 group are characterized by signs of axonal regeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. CMT2B1 inheritance is autosomal recessive.
      Defects in LMNA are the cause of Hutchinson-Gilford progeria syndrome (HGPS) [MIM:176670]. HGPS is a rare genetic disorder characterized by features reminiscent of marked premature aging. Note=HGPS is caused by the toxic accumulation of a mutant form of lamin-A/C. This mutant protein, called progerin, acts to deregulate mitosis and DNA damage signaling, leading to premature cell death and senescence. Progerin lacks the conserved ZMPSTE24/FACE1 cleavage site and therefore remains permanently farnesylated. Thus, although it can enter the nucleus and associate with the nuclear envelope, it cannot incorporate normally into the nuclear lamina.
      Defects in LMNA are the cause of cardiomyopathy dilated with hypergonadotropic hypogonadism (CMDHH) [MIM:212112]. A disorder characterized by the association of genital anomalies, hypergonadotropic hypogonadism and dilated cardiomyopathy. Patients can present other variable clinical manifestations including mental retardation, skeletal anomalies, scleroderma-like skin, graying and thinning of hair, osteoporosis. Dilated cardiomyopathy is characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia.
      Defects in LMNA are the cause of mandibuloacral dysplasia with type A lipodystrophy (MADA) [MIM:248370]. A disorder characterized by mandibular and clavicular hypoplasia, acroosteolysis, delayed closure of the cranial suture, progeroide appearance, partial alopecia, soft tissue calcinosis, joint contractures, and partial lipodystrophy with loss of subcutaneous fat from the extremities. Adipose tissue in the face, neck and trunk is normal or increased.
      Defects in LMNA are a cause of lethal tight skin contracture syndrome (LTSCS) [MIM:275210]; also known as restrictive dermopathy (RD). Lethal tight skin contracture syndrome is a rare disorder mainly characterized by intrauterine growth retardation, tight and rigid skin with erosions, prominent superficial vasculature and epidermal hyperkeratosis, facial features (small mouth, small pinched nose and micrognathia), sparse/absent eyelashes and eyebrows, mineralization defects of the skull, thin dysplastic clavicles, pulmonary hypoplasia, multiple joint contractures and an early neonatal lethal course. Liveborn children usually die within the first week of life. The overall prevalence of consanguineous cases suggested an autosomal recessive inheritance.
      Defects in LMNA are the cause of heart-hand syndrome Slovenian type (HHS-Slovenian) [MIM:610140]. Heart-hand syndrome (HHS) is a clinically and genetically heterogeneous disorder characterized by the co-occurrence of a congenital cardiac disease and limb malformations.
      Defects in LMNA are the cause of muscular dystrophy congenital LMNA-related (CMD-LMNA) [MIM:613205]. It is a form of congenital muscular dystrophy. Patients present at birth, or within the first few months of life, with hypotonia, muscle weakness and often with joint contractures.
    • Sequence similarities
      Belongs to the intermediate filament family.
    • Post-translational
      Increased phosphorylation of the lamins occurs before envelope disintegration and probably plays a role in regulating lamin associations.
      Proteolytic cleavage of the C-terminal of 18 residues of prelamin-A/C results in the production of lamin-A/C. The prelamin-A/C maturation pathway includes farnesylation of CAAX motif, ZMPSTE24/FACE1 mediated cleavage of the last three amino acids, methylation of the C-terminal cysteine and endoproteolytic removal of the last 15 C-terminal amino acids. Proteolytic cleavage requires prior farnesylation and methylation, and absence of these blocks cleavage.
      Sumoylation is necessary for the localization to the nuclear envelope.
      Farnesylation of prelamin-A/C facilitates nuclear envelope targeting.
    • Cellular localization
      Nucleus. Nucleus envelope. Farnesylation of prelamin-A/C facilitates nuclear envelope targeting and subsequent cleaveage by ZMPSTE24/FACE1 to remove the farnesyl group produces mature lamin-A/C, which can then be inserted into the nuclear lamina. EMD is required for proper localization of non-farnesylated prelamin-A/C.
    • Information by UniProt
    • Database links
    • Alternative names
      • 70 kDa lamin antibody
      • Cardiomyopathy dilated 1A (autosomal dominant) antibody
      • CDCD1 antibody
      • CDDC antibody
      • CMD1A antibody
      • CMT2B1 antibody
      • EMD2 antibody
      • FPL antibody
      • FPLD antibody
      • FPLD2 antibody
      • HGPS antibody
      • IDC antibody
      • Lamin A antibody
      • Lamin A/C antibody
      • Lamin A/C like 1 antibody
      • Lamin antibody
      • Lamin C antibody
      • Lamin-A/C antibody
      • LDP1 antibody
      • LFP antibody
      • LGMD1B antibody
      • Limb girdle muscular dystrophy 1B (autosomal dominant) antibody
      • LMN 1 antibody
      • LMN A antibody
      • LMN C antibody
      • LMN1 antibody
      • LMNA antibody
      • LMNA_HUMAN antibody
      • LMNC antibody
      • LMNL1 antibody
      • Prelamin A/C antibody
      • PRO1 antibody
      • Renal carcinoma antigen NY REN 32 antibody
      • Renal carcinoma antigen NY-REN-32 antibody
      • Renal carcinoma antigen NYREN32 antibody
      see all


    • All lanes : Anti-Lamin A + C antibody [EPR4519(2)] (ab169532) at 1/5000 dilution

      Lane 1 : Mouse brain tissue lysate
      Lane 2 : Mouse heart tissue lysate
      Lane 3 : Mouse kidney tissue lysate
      Lane 4 : Mouse spleen tissue lysate
      Lane 5 : Rat brain tissue lysate
      Lane 6 : Rat heart tissue lysate
      Lane 7 : Rat kidney tissue lysate
      Lane 8 : Rat spleen tissue lysate

      Lysates/proteins at 10 µg per lane.

      All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/2000 dilution

      Predicted band size: 74 kDa
      Observed band size: 74 kDa

      Exposure time: 30 seconds

      Blocking and Diluting buffer 5% NFDM /TBST 

      65-74 kDa: full length;
      45-50 kDa: cleavage forms

    • ab169532 showing +ve staining in Human normal colon tissue.

    • ab169532 showing +ve staining in Human normal brain tissue.

    • ab169532 showing +ve staining in Human normal kidney tissue.

    • ab169532 showing +ve staining in Human normal tonsil tissue.

    • Immunohistochemical analysis of paraffin-embedded Human skin tissue labeling Lamin A + C with ab169532 at 1/250 dilution.
    • Immunohistochemical analysis of paraffin-embedded Human uterus tissue labeling Lamin A + C with ab169532 at 1/250 dilution.
    • All lanes : Anti-Lamin A + C antibody [EPR4519(2)] (ab169532) at 1/10000 dilution

      Lane 1 : PC-12 cell lysate
      Lane 2 : THP-1 cell lysate
      Lane 3 : HeLa + Staurosporine cell lysate
      Lane 4 : HeLa cell lysate

      Lysates/proteins at 10 µg per lane.

      All lanes : HRP labeled goat anti-rabbit at 1/2000 dilution

      Predicted band size: 74 kDa


    This product has been referenced in:
    • Ma Y  et al. Lamin B2 binding to minichromosome maintenance complex component 7 promotes non-small cell lung carcinogenesis. Oncotarget 8:104813-104830 (2017). Read more (PubMed: 29285216) »

    See 1 Publication for this product

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab169532.
    Please use the links above to contact us or submit feedback about this product.


    Sign up